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Treatment of acute myeloid leukemia (AML), an aggressive and heterogeneous hematological malignancy, remains
a challenge. Despite advances in our understanding of the complex genetics and biology of AML pathophysiology,
these findings have been translated to the clinic with only limited success, and poor outcomes persist for the
majority of patients. Thus, novel treatment strategies are clearly needed for achieving deeper and prolonged
remissions and for avoiding the development of resistance. Due to its profound role in (cancer) stem cell biology
and differentiation, the Hedgehog (HH)/Glioma-associated Oncogene Homolog (GLI) signaling pathway may be an
attractive novel therapeutic target in AML. In this review, we aim to provide a critical and concise overview of the
currently known potential and challenges of HH/GLI targeting. We describe the biological role of the HH/GLI
pathway in AML pathophysiology. We specifically focus on ways of targeting non-canonical HH/GLI signaling in
AML, particularly in combination with standard treatment regimens, which may overcome some hurdles observed
with approved HH pathway inhibitors in solid tumors.
Keywords: Acute myeloid leukemia, Cancer stem cells, Hedgehog (HH) signaling, GLI proteins, Non-canonical
Hedgehog/GLI signaling, Combination therapyBackground
Acute myeloid leukemia (AML) is an aggressive
hematological neoplasm with a highly diverse clinical
course. Known prognostic factors include age, complex
karyotype, mutations, presence of elevated white blood
cell counts, antecedent hematologic disease, and prior
chemo/radiotherapy for another malignancy [1]. With
the advent of newer technologies such as next gener-
ation sequencing, the prognostic relevance of specific
mutations and karyotypes is becoming more and more
recognized and is reflected in the current revision of the
AML classification of the World Health Organization
(WHO) [2]. The 2016 revision updates the prior classifi-
cation in an attempt to incorporate new clinical, morpho-
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contrast, in the older French-American-British (FAB) cri-
teria, the classification of AML is solely based upon
morphology, i.e. the degree of cell differentiation and mat-
uration [3]. Moreover, the FAB classification used a cut-off
of ≥ 30% blasts in the blood or bone marrow (BM)
for AML diagnosis, which was adapted by the WHO
to ≥ 20% since several studies reported a similar
prognosis in terms of survival for patients with 20–29%
blasts as for those with ≥ 30% blasts in the BM [4–8].
In order to be successful, AML treatment mainly re-
quires management of the BM and systemic disease.
Therefore, AML therapy is based on systemic combin-
ation chemotherapy and usually includes two treatment
phases: firstly, the achievement of remission (induction)
and secondly, the consolidation of remission. Current
treatment for previously untreated AML in fit/younger
patients is composed of two therapeutics, cytarabine
(Ara-C) and an anthracycline such as daunorubicin
(“7 + 3 induction therapy”), with a complete response/
remission (CR) rate of about 65% [9]. This can optionallyle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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little available data it is not possible to infer a superiority
of this extended combination. Another optional addition
is etoposide [11], which might prolong the duration of the
initial response. Moreover, different forms and doses of
anthracycline can influence the treatment outcome, so it
was found that in younger patients idarubicin is more ef-
fective than daunorubicin, however, the doses tested have
not been the same [9, 12–14] and no significant survival
benefit was found [15].
A randomized study by the Eastern Cooperative
Oncology Group (ECOG) showed that after only a short
term CR all patients without consolidation therapy re-
lapsed [16] and only few successful chemotherapies
without relapse after a single treatment cycle have been
reported [17]. Therefore, a consolidation therapy after
initial remission is mandatory in order to achieve a cura-
tive effect. The current efforts in consolidation therapy
comprise relatively short and intense or higher doses of
chemotherapy with regimens also used in initial treat-
ment as well as autologous or allogeneic hematopoietic
stem cell (HSC) transplantation after BM chemoradia-
tion/ablative therapy [18].
Older or unfit patients, however, often do not endure
a high dose remission initiating treatment. Thus, those
patients benefit more from receiving low-dose Ara-C
[19] or hypomethylating agents like decitabine and aza-
citidine (5-Aza), which was initially approved for treat-
ment of myelodysplastic syndrome (MDS) [20, 21].
Preliminary data from a recent phase III trial showed
comparable overall survival for patients older than 65
years receiving either 5-Aza, conventional therapy of
best supportive care or the 7 + 3 induction therapy [22].
Despite achievement of CR after initiation/consolidation
therapy the majority of AML patients eventually relapse,
either due to a lack of response or the development of
drug resistance. Thus, relapsed/refractory AML (rrAML)
is rather common and unfortunately very difficult to man-
age due to limited availability of effective therapies [23].
Currently, treatment of rrAML, depending on the patient’s
fitness, includes non-/intensive chemotherapy regimens
and/or HSC transplantation as well as a combination of
investigational agents and high dose Ara-C, often also the
enrollment in clinical trials [24]. However, standard AML
treatment has not seen many modifications within the last
decades and new therapeutic approaches are needed, es-
pecially for unfit patients and those with negative prog-
nostic factors, which is highly challenging considering the
heterogeneity of the various prognostic and molecular
AML subgroups. This need is reflected in the numerous
new treatment options presently under development and
in clinical trials including combination approaches, novel
formulations of cytotoxic chemotherapy and hypomethy-
lating agents as well as other epigenetic modifiers,antibody-drug conjugates and molecularly targeted agents
like cell cycle and signaling inhibitors [25–27].
Moreover, since there is increasing evidence that levels
of minimal residual disease (MRD) after induction ther-
apy are a relevant risk factor, the monitoring of MRD
during remissions has already entered the clinical trial
stage in AML [28]. In the long term, it is likely that the
introduction of MRD assessments will provide early end
points in clinical trials and thus will modify the clinical
landscape. However, to achieve this goal, standardization
and harmonization processes of MRD detection methods
and assays are required [28, 29]. Increasing the know-
ledge of the cellular MRD composition might also help
in identifying relapse initiating cell types, which we will
further discuss in the next section.
AML biology and the cancer stem cell concept
AML is based on a differentiation defect of hematopoietic
stem and progenitor cells (HSPCs) in the BM, resulting in
accumulation of immature blast cells that displace the
normal hematopoietic system. Within the BM microenvir-
onment, AML blasts interact and communicate with
stromal and immune cells, thereby impacting on the
pathogenesis of the disease. In particular, leukemic blasts
create their own protective niche by reprogramming
mesenchymal stromal cells to selectively support leukemic
cells, while simultaneously suppressing the normal
hematopoiesis [30]. A common belief is that in AML a
hierarchy of cells exists, with the most primitive types of
cells residing in a quiescent state and protected in the
leukemic niche representing the “leukemia initiating cells”
or “cancer stem cells”. These cells are highly resistant
to most chemotherapeutic drugs that mainly target
cycling cells, and often give rise to MRD, which ul-
timately causes relapses [31, 32]. In a novel modifica-
tion of this concept, the existence of pre-leukemic
stem cells is also discussed [33, 34].
Stem cell pathways such as Wnt, Notch or Hedgehog
(HH)/GLI signaling have been implicated in cellular self-
renewal and resistance to chemotherapy of various can-
cer stem cell types [35].
The recent approval of small molecule inhibitors of
HH/GLI signaling for the treatment of advanced and
metastatic non-melanoma skin cancer has sparked high
expectations that HH/GLI targeting may prove an effi-
cient and even curative therapeutic approach for a range
of solid and hematological malignancies [36–38]. How-
ever, several recent clinical trials have largely failed to
demonstrate a therapeutic benefit of HH/GLI inhibitors
that target the essential pathway effector Smoothened
(SMO) in a variety of solid cancer entities [39]. These
disappointing trial data dampened the enthusiasm of the
field for treating HH-associated cancers by blocking
SMO function but at the same time opened up new
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hibition of the critical oncogenic downstream HH effec-
tors, the GLI zinc-finger transcription factors. There is
substantial preclinical evidence that inhibition of SMO-
independent GLI activation (henceforth referred to as
non-canonical HH/GLI signaling) may provide a pro-
nounced therapeutic benefit, also in settings with ac-
quired or a priori resistance to SMO inhibitors [40–44].
In the following chapters, we aim to provide a concise
overview of recent studies addressing the role of HH/
GLI signaling in AML pathogenesis and its possible
therapeutic implications. We summarize selected key
mechanisms of non-canonical HH/GLI signal transduc-
tion, concentrating on novel insights into SMO-
independent regulation of GLI activity by multiple onco-
genic signal cues. Based on these cross-talk signalingFig. 1 Model of oncogenic HH/GLI signaling in AML. Activation of HH/GLI
derived from adjacent BM stromal cells expressing low levels of the HH inh
chemoresistance, and promote leukemogenesis by epigenetically repressing
FLT3/STAT5 signaling. LIC: leukemia initiating cell; Me: DNA methylationevents, we discuss possible therapeutic approaches tack-
ling AML by targeting oncogenic GLI proteins with
novel compounds and rational combination treatments.
HH/GLI signaling in AML biology and therapy
With regard to AML biology and pathogenesis, the HH
pathway has recently received much attention for its
implication in leukemic stem cell regulation and in the
orchestration of acquired drug resistance of poor prog-
nostic AML (summarized in Fig. 1). Using modified hu-
man myeloid cell lines (HL60), Li and colleagues [45]
showed that myeloid cells that acquired radio- (HL60/
RX) as well as drug-resistance (HL60/ADR) express
higher levels of SMO and GLI1. In line, the radioresis-
tance was overcome by inhibition of the HH pathway via
the SMO antagonist LDE225 (sonidegib/erismodegib)in leukemic (stem) cells of AML patients can be activated by HH ligand
ibitor HHIP. GLI expression in AML cells can enhance radio- and
cell-cycle inhibitors (e.g. p15) or by synergistic cross-talk with oncogenic
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GLI1/PI3K/AKT/NF-kB pathway. Thus, LDE225 treat-
ment resulted in increased apoptosis induction and
decreased DNA repair ability upon radiation.
Further evidence for an involvement of HH/GLI sig-
naling in drug resistance was provided by Zahreddine
et al. who analyzed primary tumor samples of patients
that relapsed after monotherapy with ribavirin (an in-
hibitor of the eukaryotic translation initiation factor
eIF4E) [46]. The authors observed an association of
relapse and drug resistance with elevated levels of GLI1
and the UDP glucuronosyltransferase (UGT1A), which
can inactivate ribavirin by glucuronidation, thus prevent-
ing binding of this drug to its target eIF4E. GLI alone
was sufficient to drive the expression of UGT1A and
accounted for drug glucuronidation. Accordingly, in
vitro treatment of patient samples with previously failed
induction therapy with the SMO inhibitor vismodegib
(GDC-0449) potentiated the effects of cytarabine and
ribavirin, providing a rationale for combination of HH
inhibitors with conventional treatment regimes. Cur-
rently, a clinical trial using ribavirin and vismodegib with
or without decitabine in AML is in the recruitment
phase (clinical trial number NCT02073838). Patients
with AML M4 or M5 FAB subtype or high eIF4E are
eligible. All patients must have failed primary therapy
(defined as two induction chemotherapies), must have
relapsed, or must not be suitable candidates for intensive
induction chemotherapy.
In addition, HH/GLI targeting also bears potential for
those patients that do not tolerate aggressive therapeutic
regimes. In particular, a combination of these antago-
nists with 5-Aza can be envisaged. Tibes and colleagues
conducted an RNA interference sensitizer screen to
identify gene targets of distinct regions presumably en-
hancing 5-Aza therapy [47]. Several HH pathway mole-
cules could be identified, among them SMO, which was
subsequently evaluated as a therapeutic target in vitro
using seven heterogeneous AML cell lines. In these as-
says, the authors identified cytotoxic synergy of LDE225
and vismodegib with 5-Aza.
In fact, several clinical trials using SMO inhibitors
alone or in combination with compounds blocking
driver mechanisms in AML have already been initiated.
For instance, the potency of the SMO inhibitor glasdegib
(PF-04449913) alone or in combination with e.g. 5-Aza or
chemotherapy is being investigated in several clinical trials
for hematologic malignancies including MDS and AML
(http://clinicaltrials.org, NCT01842646, NCT01841333,
NCT01546038, NCT02367456). It is noteworthy that in a
phase 2 trial with untreated AML and high-risk MDS
patients, low dose Ara-C chemotherapy in combination
with glasdegib improved overall survival when compared
to chemotherapy only [48]. The community is keenlyawaiting the outcome of these trials, also in light of the
discussion of SMO-dependent and independent regulation
of oncogenic GLI activity.
Indeed, besides targeting SMO, direct inhibition of
GLI is a promising option, particularly in settings of
SMO-independent GLI activation. On basis of two com-
prehensive clinical patient cohorts, a significant negative
prognostic impact of GLI2 expression in AML could be
established by Wellbrock and colleagues [49]. In the first
cohort, based on the AMLSG 07–04 trial comprising
104 patient samples, the presence of GLI2 expression
significantly shortened event-free survival, relapse-free
survival, and overall survival and was correlated with
FLT3 mutational status. Analysis of a second, independ-
ent cohort of 290 AML samples confirmed the negative
impact of GLI2 on event-free survival and overall
survival.
The relevance of GLI expression for disease pathogen-
esis was further strongly supported by in vitro and in
vivo experimental data using treatment of AML cell
lines by GANT61, a GLI antagonist tool compound [50],
and GLI shRNA approaches as well as an adoptive trans-
fer model of AML. Of note, mice transplanted with
GLI1/GLI2 double-depleted AML cells displayed a mod-
erate yet significant increase in survival compared to
controls. These data clearly support the development of
clinically useful GLI antagonists for therapy.
Further support for an association of FLT3-mutated
AML and HH pathway activation via the STAT pathway
has recently been provided by the Matsui group [51]
using transgenic mouse models with a combination of
constitutively active SMO and internal tandem duplica-
tions (ITD) of FLT3. Combined treatment using the
SMO inhibitor saridegib/IPI-926 and the kinase inhibitor
sorafenib resulted in reduced tumor load and increased
survival of the mice. The clinical impact was further
supported by the identification of increased GLI2 ex-
pression in FLT3-ITD positive AML patients.
In tumor cells, both autocrine and paracrine HH
pathway activation has been described [52]. In AML,
in contrast to some solid tumors, the microenviron-
ment appears to play the dominant role in providing
such activation inducing ligands to leukemic cells.
Wellbrock and colleagues [49] observed that AML pa-
tients displayed increased serum levels of Desert
Hedgehog (DHH) that was obviously produced and shed
into the blood by the BM microenvironment rather
than the AML cells. Similar observations have been
made by other authors, reporting an increased expression
of Sonic Hedgehog (SHH), SMO, and GLI1 in BM stromal
cells of MDS patients, compared to healthy donors that
are known to express Indian Hedgehog (IHH) and SMO
[53], with even higher HH effector levels in post-MDS
AML [54].
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protein binding to and thus inhibiting HH ligand func-
tion, is produced by healthy BM stromal cells and has
been shown to have the potential of suppressing prolifer-
ation of leukemic cells. In contrast, HHIP expression in
BM stromal cells derived from AML and MDS patients
was reduced [55], which was accompanied by the ability
of these cells to support leukemic cell proliferation. This
reduced HHIP expression might thus contribute to the
progression of AML and MDS. Moreover, pretreatment
with 5-Aza induced demethylation of the HHIP gene
and partial restoration of HHIP expression, thereby
reducing the supportive effect of the primary AML/
MDS stromal cells on the malignant cells and under-
lining the function of HHIP as an endogenous HH
ligand inhibitor.
More recently, GLI1 expression has been shown to
correlate with increased expression of DNA methyl-
transferase 1 (DNMT1) and high-risk MDS. Of note,
knock-down of GLI1 in MDS cells not only decreased
survival, proliferation and DNMT1 expression but alsoFig. 2 Canonical, ligand-dependent HH/GLI signaling. a In the absence of l
allowing the phosphorylation and proteolyic processing of full-length and
within the primary cilium. In the nucleus, GLIR binds to promoters of direct
and post-translationally modified HH protein to its receptor PTCH abolishes
activation of SMO. Active SMO prevents GLIR processing and induces releas
to the nucleus, where it induces HH target gene expressionenhanced the demethylating efficacy of 5-Aza, resulting
in lower methylation of the tumor suppressor gene p15
promoter and enhanced p15 expression, respectively
[56]. Combined use of GLI antagonists with demethylat-
ing drugs may therefore show improved therapeutic
efficacy.
In line with an oncogenic role of HH/GLI in MDS and
AML, a positive correlation between GLI1 expression
and percentage of AML blasts, as defined by CD34
expression, has recently been observed in BM [57]. Also
in the cell lines used in this study, in vitro treatment
with the GLI antagonist GANT61 resulted in reduced
proliferative and colony forming characteristics and
displayed synergistic cytotoxicity with Ara-C [57].
The potential of targeting non-canonical HH/GLI
signaling in AML
While canonical activation of the GLI transcription
factors depends on activation of the essential pathway
effector SMO either by ligand-dependent or genetic in-
activation of the HH receptor Patched (PTCH) (Fig. 2)igand, PTCH represses the ciliary translocation and activation of SMO,
SUFU-bound GLI protein into its C-terminally truncated repressor (GLIR)
HH-target genes to prevent their transcription. b Binding of processed
the inhibitory effect of PTCH on SMO, allowing ciliary transport and
e of active GLI from its repressor SUFU. GLI activator (GLIA) translocates
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transcription factors is independent of SMO activation,
and can be mediated by a variety of distinct key onco-
genic signaling cascades [44, 62, 63]. This has important
therapeutic implications, as SMO-independent GLI acti-
vation results in SMO inhibitor resistance, a clinically
relevant problem that may account for the disappointing
results from several trials using SMO inhibitors (e.g.
vismodegib, sonidegib, saridegib) [39, 64]. Further, the
severity of adverse effects induced by SMO inhibitors
(e.g. muscle cramps) limits the prolonged administration
of such drugs [65, 66]. We therefore propose that direct
targeting of oncogenic GLI transcription factors, as
has been shown in several proof of concept studies
[50, 67, 68], in combination with strategies interfering
with oncogenic cues promoting GLI activity in AML
will provide a therapeutic benefit compared to single
treatment protocols (Fig. 3).
In the following section, we will provide an overview
of mechanistic models that can account for SMO
inhibitor resistance and will summarize several represen-
tative and seminal studies that have revealed SMO-
independent positive or negative regulation of GLI acti-
vity by oncogenic signaling pathways and epigenetic
factors (reviewed in [44, 69]). Given the critical role of
GLI transcription factors in the development and pro-
gression of several leukemic diseases including AML, a
detailed understanding of “druggable” cross-talk pathwaysFig. 3 Non-canonical control of GLI activity by oncogenic mechanisms inv
molecule targeting of these GLI regulatory signals with clinically approved/
such as direct GLI antagonists may generate efficient therapeutic effects. H
[68], GANT61: direct GLI antagonist 61 [50], Glab B: glabrescione B (direct Gcontrolling oncogenic GLI function will provide the
rationale for the design and evaluation of novel, efficacious
combination treatments in AML.
Oncogenic signals regulating GLI activity
The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK signal-
ing cascades control multiple cellular functions such as
transcription, translation, proliferation, growth and sur-
vival. The aberrant activation of these oncogenic signals
plays major roles in numerous malignant entities and
therapeutic targeting of PI3K/AKT/mTOR and MEK/
ERK signaling is a promising approach, intensely tested
in clinical trials using selective small-molecule inhibitors
(reviewed in [70–72]). Cross-talk of HH signaling with
both PI3K/AKT and RAS/RAF/MEK pathways has been
described in many cancer entities including melanoma,
prostate cancer, non-melanoma skin cancer, glioma and
leukemia. For instance, the cross-talk of HH/GLI and
PI3K/AKT has an impact on GLI1 and GLI2 expression,
protein stability, nuclear localization and transcriptional
activity [73–80].
Another study dealing with human pancreatic cancer
revealed an inhibitory effect on tumorigenic cancer stem
cells through the combined blockade of HH and mTOR
signaling using SMO and mTOR inhibitors together
with standard chemotherapy [81]. These findings were
supported by Miyazaki et al. who described that com-
bined inhibition of HH and mTOR signaling eliminatesolving kinases, and epigenetic modulators. Rationale-based small-
suitable drugs alone or in combination with HH pathway inhibitors
PI-1: Hedgehog Pathway Inhibitor-1 acting at the level of GLI proteins
LI inhibitor interfering with DNA binding) [67], HDACi: HDAC inhibitors
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ously mentioned study, they used the direct GLI antag-
onist GANT61, which had a stronger negative effect on
sphere formation and cell viability than the SMO inhibi-
tor cyclopamine, even in the absence of additional stand-
ard chemotherapy [82].
Moreover, the signal integration of non-canonical
GLI1/2 activation by PI3K/AKT was also deciphered as
a novel potential therapeutic target because combination
of the GLI inhibitor GANT61 and the AKT inhibitor
perifosine resulted in synergistically suppressed tumor
growth and induced apoptosis in renal cell carcinoma
models [73]. Recently, Kern and colleagues reported a
synergistic therapeutic effect in cells from a subgroup of
CLL patients through combined targeting of GLI and
PI3K/AKT/mTOR signaling [83]. Moreover, GLI1 pro-
tein can be phosphorylated by the ribosomal S6-kinase 1
(S6K1), a critical downstream effector of PI3K/AKT and
MEK/ERK signaling. Notably, mTOR/S6K1-mediated
phosphorylation appears to facilitate the release of GLI1
protein from its cytoplasmic repressor SUFU, thereby
enhancing the overall oncogenicity of GLI1 in esophageal
adenocarcinoma cells. In line with these mechanistic
findings, combined inhibition of HH/GLI and mTOR/
S6K1 activity synergistically reduced the survival of GLI
expressing esophageal cancer cells [84]. Taken together,
these studies support a pronounced therapeutic benefit of
combined HH/PI3K/mTOR targeting in selected malig-
nant diseases. Whether similar cooperative mechanisms
operate in AML pathogenesis remains to be addressed.
GLI transcriptional activity is also positively regulated
by RAS/RAF/MEK/ERK signaling, for instance in melan-
oma and pancreatic cancer [76, 85, 86]. Mechanistically,
direct phosphorylation of GLI proteins by ERK kinases
can enhance transcriptional GLI activity [86, 87]. Cross-
talk of epidermal growth factor receptor (EGFR) signal-
ing with HH/GLI also depends on MEK/ERK activation,
yet involves another mechanism of cooperation. HH/
EGFR signal integration relies on cooperativity of se-
lected transcription factors simultaneously induced by
concomitant HH/EGFR signaling. These studies revealed
that EGFR can synergize with HH/GLI via MEK/ERK-
dependent activation of JUN/AP-1 transcription factors,
resulting in synergistic induction of common HH/EGF
target genes and oncogenic transformation [78–80].
Additional druggable kinases modulating oncogenic
GLI activity include atypical Protein Kinase C (aPKC or
PKC iota/gamma) and members of the dual-specificity
tyrosine phosphorylation regulated kinase (DYRK) family.
aPKC has been shown to directly phosphorylate GLI1
at amino acid residues located in the zinc finger DNA
binding domain, thereby enhancing DNA binding and
maximum transcriptional activity of GLI. Notably, SMO
inhibitor resistance can be mediated by hyperactivationof aPKC, suggesting that aPKC targeting in patients
unresponsive to SMO inhibitors may overcome SMO
inhibitor resistance, as shown in in vitro models [42, 88].
DYRK kinases can exert positive or negative effects on
the transcriptional activity of GLI. DYRK1A-mediated
phosphorylation of GLI1 can increase GLI1 activity by
promoting its nuclear localization [89]. Recently, our
own group has provided evidence for a critical positive
role of DYRK1B rather than DYRK1A in various human
cancer entities and shown that genetic and pharma-
cologic DYRK1B targeting can efficiently eliminate GLI1-
dependent tumor-initiating pancreatic cancer cells [90].
Aside from this, a KRAS/DYRK1B network can also
redirect autocrine HH signaling towards a paracrine
mode in human pancreatic adenocarcinoma [91]. Un-
like DYRK1 proteins, DYRK2 represses GLI activity
by promoting proteasomal degradation of GLI2 via
direct phosphorylation [92]. Pharmacologic inhibition
of oncogenic GLI proteins therefore requires clinically
useable drugs that selectively target DYRK1 family
members.
Casein kinase 1-alpha (CK1A) and protein kinase A
(PKA) can be considered additional potential therapeutic
targets. Activation of CK1A by pyrvinium can promote
GLI repressor formation and GLI degradation [93].
However, as CK1A can also be an activator of HH sig-
naling, its overactivation has to be taken with precaution
[94]. Activation of PKA for instance by imiquimod, a
synthetic nucleoside analog that binds to adenosine re-
ceptors, induces GLI phosphorylation and subsequent
degradation and/or cleavage into repressor forms [95].
In addition to phosphorylation, other post-translational
modifications of GLI proteins control the oncogenic activ-
ity of GLI. Canettieri et al. have shown that acetylation of
GLI1 and GLI2 represses, while histone deacetylase
(HDAC)-mediated deacetylation increases their transcrip-
tional activity. This interplay is further regulated by a
positive feed-forward loop involving HH-induced upregu-
lation of HDAC1 [96]. The role of HDACs in promoting
HH/GLI signaling has been further supported by findings
showing that HDAC6 activity is required for the full-
activation of HH/GLI signal strength [97]. The use of
selected clinically validated HDAC inhibitors, which have
already shown promising therapeutic efficacy in AML
patients [98], in combination with GLI antagonists may
therefore be an attractive therapeutic approach in GLI-
dependent cancer entities. The finding that a novel dual
HDAC/SMO inhibitor, NL-103, can down-regulate both
HH/GLI and HDAC activity, thereby overcoming vismo-
degib resistance [99], exemplifies that dual targeting of
GLI and GLI promoting signals such as HDACs with a
single compound is feasible and an attractive option for
future therapeutic strategies including the treatment of
AML patients.
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family member bromodomain 4 (BRD4) protein has
been shown to modulate HH signaling. BRD4 can bind
to acetylated lysines in histones, enhance target gene
expression via stimulation of RNA polymerase II activity
and can be efficiently inhibited by the BRD antagonists
JQ1 and I-BET [100, 101]. BRD4 activity has been linked
to HH/GLI signaling in two parallel studies showing that
BRD4 regulates GLI transcription in a SMO- and SUFU-
independent manner by binding directly to the GLI1
and GLI2 promoters and that JQ1 reduces the binding
of BRD4 to its binding sites in the GLI promoters
[101, 102]. Intriguingly, JQ1 also inhibits BRD4-regulated
MYC activity [103], a critical driver signal in AML patho-
genesis. The impressive therapeutic activity of BRD inhibi-
tors in preclinical models of AML may therefore result
from their inhibitory effect on multiple targets including
key oncogenic players in leukemic (stem) cells such as
MYC and GLI [104–107].Conclusions
In summary, the still very high occurrence of AML
relapses upon therapy reflects the need for novel
treatment strategies. In this regard, targeting the HH/
GLI pathway in AML can be a promising therapeutic
approach, since this signaling cascade is crucially involved
not only in the regulation of cancer stem/leukemia initiat-
ing cells, but also in the development of drug resistance.
The possibility of inhibiting multiple key players in this
pathway (i.e. SMO, GLI1/GLI2) as well as the combin-
ation with other agents targeting important mechanisms
involved in AML pathology (e.g. kinase inhibitors and
epigenetic regulators such as 5-Aza, HDACi and BRD4)
provide a multitude of new treatment options. Targeting
the non-canonical HH/GLI signaling pathway by directly
interfering with the activity of the GLI transcription
factors as well as their cross-talk with other signaling
pathways (e.g. kinases) may be particularly promising,
since this alternate approach might prevent the develop-
ment of resistance and severe side effects as seen for
SMO inhibitors.
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